Mark Rubin

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. pmc Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
    Raquel Esgueva
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
    Mod Pathol 23:539-46. 2010
  2. pmc The genomic complexity of primary human prostate cancer
    Michael F Berger
    The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
    Nature 470:214-20. 2011
  3. pmc Testing mutual exclusivity of ETS rearranged prostate cancer
    Maria A Svensson
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Lab Invest 91:404-12. 2011
  4. pmc Impact of constitutional copy number variants on biological pathway evolution
    Maria Poptsova
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
    BMC Evol Biol 13:19. 2013
  5. pmc ETS rearrangements in prostate cancer
    Mark A Rubin
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Asian J Androl 14:393-9. 2012
  6. pmc FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data
    Andrea Sboner
    Program in Computational Biology and Bioinformatics, Yale University, 300 George Street, New Haven, CT 06511, USA
    Genome Biol 11:R104. 2010
  7. doi request reprint Common gene rearrangements in prostate cancer
    Mark A Rubin
    Weill Cornell Medical College, 1300 York Ave, Room C 410 A, New York, NY 10021, USA
    J Clin Oncol 29:3659-68. 2011
  8. ncbi request reprint Targeted therapy of cancer: new roles for pathologists--prostate cancer
    Mark A Rubin
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    Mod Pathol 21:S44-55. 2008
  9. pmc Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies
    Harveer Dev
    Lefrak Center of Robotic Surgery and Institute for Prostate Cancer, Brady Foundation Department of Urology, Weill Cornell Medical College, New York, NY, USA
    J Transl Med 9:121. 2011
  10. doi request reprint High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development
    Dong Lin
    Authors Affiliations Vancouver Prostate Centre Department of Urologic Sciences, Faculty of Medicine, University of British Columbia Departments of Experimental Therapeutics and Radiation Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada Departments of Medicine and Pathology and Laboratory Medicine, Weill Cornell Cancer Center, Weill Cornell Medical College, New York, New York
    Cancer Res 74:1272-83. 2014

Research Grants

  1. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2002
  2. "Molecular Signatures of Lethal and Indolent Prostate Cancer"
    Mark A Rubin; Fiscal Year: 2010
  3. Towards Understanding Prostate Cancer Heterogeneity
    Mark Rubin; Fiscal Year: 2009
  4. "Molecular Signatures of Lethal and Indolent Prostate Cancer"
    Mark Rubin; Fiscal Year: 2009
  5. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2006
  6. "Molecular Signatures of Lethal and Indolent Prostate Cancer"
    Mark Rubin; Fiscal Year: 2006
  7. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2005
  8. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2004
  9. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2004
  10. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2003

Detail Information

Publications82

  1. pmc Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
    Raquel Esgueva
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
    Mod Pathol 23:539-46. 2010
    ..Incorporation of these less common ERG rearranged prostate cancer fusion assays could further increase the sensitivity of the current PCR-based approaches...
  2. pmc The genomic complexity of primary human prostate cancer
    Michael F Berger
    The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
    Nature 470:214-20. 2011
    ..Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms...
  3. pmc Testing mutual exclusivity of ETS rearranged prostate cancer
    Maria A Svensson
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Lab Invest 91:404-12. 2011
    ..In conclusion, we provide further evidence for prostate cancer tumor heterogeneity with the identification of multiple concurrent gene rearrangements...
  4. pmc Impact of constitutional copy number variants on biological pathway evolution
    Maria Poptsova
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
    BMC Evol Biol 13:19. 2013
    ....
  5. pmc ETS rearrangements in prostate cancer
    Mark A Rubin
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Asian J Androl 14:393-9. 2012
    ....
  6. pmc FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data
    Andrea Sboner
    Program in Computational Biology and Bioinformatics, Yale University, 300 George Street, New Haven, CT 06511, USA
    Genome Biol 11:R104. 2010
    ..It also has a module to identify exact sequences at breakpoint junctions. FusionSeq detected known and novel fusions in a specially sequenced calibration data set, including eight cancers with and without known rearrangements...
  7. doi request reprint Common gene rearrangements in prostate cancer
    Mark A Rubin
    Weill Cornell Medical College, 1300 York Ave, Room C 410 A, New York, NY 10021, USA
    J Clin Oncol 29:3659-68. 2011
    ....
  8. ncbi request reprint Targeted therapy of cancer: new roles for pathologists--prostate cancer
    Mark A Rubin
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    Mod Pathol 21:S44-55. 2008
    ..However, in 2007, the mainstay of treatment for advanced PCA remains androgen ablation therapy as originally introduced in the early 1940s...
  9. pmc Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies
    Harveer Dev
    Lefrak Center of Robotic Surgery and Institute for Prostate Cancer, Brady Foundation Department of Urology, Weill Cornell Medical College, New York, NY, USA
    J Transl Med 9:121. 2011
    ..We seek to establish the integrity of our biobanking process by measuring the RNA quality of specimens derived from robotic-assisted laparoscopic radical prostatectomy...
  10. doi request reprint High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development
    Dong Lin
    Authors Affiliations Vancouver Prostate Centre Department of Urologic Sciences, Faculty of Medicine, University of British Columbia Departments of Experimental Therapeutics and Radiation Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada Departments of Medicine and Pathology and Laboratory Medicine, Weill Cornell Cancer Center, Weill Cornell Medical College, New York, New York
    Cancer Res 74:1272-83. 2014
    ..We predict that these next-generation models will be transformative for advancing mechanistic understanding of disease progression, response to therapy, and personalized oncology...
  11. doi request reprint Anatomical retro-apical technique of synchronous (posterior and anterior) urethral transection: a novel approach for ameliorating apical margin positivity during robotic radical prostatectomy
    Ashutosh K Tewari
    Lefrak Center of Robotic Surgery, James Buchanan Brady Foundation Department of Urology, Weill Cornell Medical College New York Presbyterian Hospital, New York, NY 10065, USA
    BJU Int 106:1364-73. 2010
    ....
  12. pmc N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer
    Dorothee Pflueger
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    Neoplasia 11:804-11. 2009
    ..Broader implications of this study support the use of RNA sequencing to discover novel cancer translocations...
  13. pmc Molecular sampling of prostate cancer: a dilemma for predicting disease progression
    Andrea Sboner
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA
    BMC Med Genomics 3:8. 2010
    ..Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models...
  14. pmc KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis
    Goutham Narla
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Clin Invest 118:2711-21. 2008
    ..Together, these findings demonstrate that KLF6-SV1 expression levels in PCa tumors at the time of diagnosis can predict the metastatic behavior of the tumor; thus, KLF-SV1 may represent a novel therapeutic target...
  15. ncbi request reprint A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk
    Goutham Narla
    Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer Res 65:1213-22. 2005
    ....
  16. pmc Distinct genomic aberrations associated with ERG rearranged prostate cancer
    Francesca Demichelis
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY 10065
    Genes Chromosomes Cancer 48:366-80. 2009
    ..This study provides further support to define a distinct molecular subtype of prostate cancer based on the presence of ETS gene rearrangements...
  17. pmc SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer
    David S Rickman
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10021, USA
    Cancer Res 69:2734-8. 2009
    ..g., trans-splicing)...
  18. pmc Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model
    Sue Ellen Touma
    Department of Pharmacology, Weill Cornell Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA
    Biochem Pharmacol 78:1127-38. 2009
    ..Our data indicate that this reduction in ALDH1A2 protein is an early event in human prostate cancer...
  19. pmc Antibody-based detection of ERG rearrangement-positive prostate cancer
    Kyung Park
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Neoplasia 12:590-8. 2010
    ..Given the ease of performing IHC versus FISH, ERG protein expression may be useful for molecularly subtyping prostate cancer based on ERG rearrangement status and suggests clinical utility in prostate needle biopsy evaluation...
  20. pmc ERG rearrangement metastasis patterns in locally advanced prostate cancer
    Sven Perner
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10065, USA
    Urology 75:762-7. 2010
    ..Recent studies characterizing ERG-rearranged PCa possessing intrafocal homogeneity but interfocal heterogeneity support this hypothesis...
  21. ncbi request reprint APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers
    Amy V Gerstein
    Department of Pathology, Institute of Cancer Genetics, Columbia University, New York, New York, USA
    Genes Chromosomes Cancer 34:9-16. 2002
    ..These results suggest that CTNNB1 signaling plays a critical role in the development of a significant fraction of prostate cancers. Moreover, they provide the first evidence that hTRCP1 plays a role in human neoplasia...
  22. ncbi request reprint Visual cues as a surrogate for tactile feedback during robotic-assisted laparoscopic prostatectomy: posterolateral margin rates in 1340 consecutive patients
    Ashutosh K Tewari
    LeFrak Center of Robotic Surgery and Institute of Prostate Cancer, James Buchanan Brady Foundation Department of Urology, Weill Medical Collage, Cornell University, 525 East 68th Street, Starr 900, New York, NY 10065, USA
    BJU Int 106:528-36. 2010
    ..e. the ability to feel when vision is greatly enhanced, as the lack of tactile feedback during RALP is often cited as a disadvantage of robotic surgery, interfering with a surgeon's ability to make intraoperative oncological decisions...
  23. pmc TMPRSS2-ETS fusion prostate cancer: biological and clinical implications
    Francesca Demichelis
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Pathol 60:1185-6. 2007
  24. ncbi request reprint Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities
    Scott E Eggener
    J Urol 178:2260-7. 2007
    ....
  25. ncbi request reprint TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion
    Sven Perner
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115 6110, USA
    Am J Surg Pathol 31:882-8. 2007
    ..Furthermore, its clinical application as a biomarker and ancillary diagnostic test is promising given its high specificity...
  26. ncbi request reprint Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases
    Jacqueline Banyard
    Vascular Biology Program, Department of Surgery, Children s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 13:2634-42. 2007
    ..The purpose of this study was to determine the expression of collagen XXIII in human prostate cancer and investigate its relationship with disease progression...
  27. ncbi request reprint Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer
    Rohit Mehra
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Mod Pathol 20:538-44. 2007
    ....
  28. pmc Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer
    Pamela L Paris
    Department of Urology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Neoplasia 8:1083-9. 2006
    ..Matched primaries and lymph node metastases showed very similar copy number profiles that are distinct from primary tumors that fail to metastasize...
  29. pmc Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer
    Bharathi Laxman
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 8:885-8. 2006
    ..These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer...
  30. ncbi request reprint TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
    Sven Perner
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115 6110, USA
    Cancer Res 66:8337-41. 2006
    ..The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement...
  31. ncbi request reprint Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells
    Ming Zhou
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Am J Surg Pathol 27:365-71. 2003
    ..We recommend this basal cell cocktail for routine Pca diagnostic work-up...
  32. ncbi request reprint Integrative biology of prostate cancer progression
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Annu Rev Pathol 1:243-71. 2006
    ..This review addresses candidate genes involved in prostate cancer pathogenesis in a biological and clinical context and demonstrates how integrated analysis of high-throughput data augments our understanding of prostate cancer...
  33. doi request reprint Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort
    Lorelei A Mucci
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:249-51. 2008
    ..We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer...
  34. doi request reprint A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis
    Sven Perner
    Mod Pathol 21:1056; author reply 1056-7. 2008
  35. pmc The role of SPINK1 in ETS rearrangement-negative prostate cancers
    Scott A Tomlins
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 13:519-28. 2008
    ..We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers...
  36. pmc Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications
    Juan Miguel Mosquera
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Clin Cancer Res 14:3380-5. 2008
    ..This may have significant clinical implications given that TMPRSS2-ERG fusion prostate cancer is associated with a more aggressive clinical course...
  37. pmc Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Cancer Inst 100:815-25. 2008
    ....
  38. doi request reprint Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer
    Kirsten D Mertz
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Int J Cancer 123:569-76. 2008
    ..Distinct molecular subtypes of ccRCC with prognostic relevance were identified, and the CK7/CK19 expressing subtype is associated with better outcome...
  39. pmc Detection of early prostate cancer using a hepsin-targeted imaging agent
    Kimberly A Kelly
    Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Cancer Res 68:2286-91. 2008
    ..HPN imaging may provide a new method for detection of prostate cancer...
  40. doi request reprint Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy
    Yilin C Neeley
    Department of Urology, Surgery, and Pathology, University of Michigan Ann Arbor, Michigan, USA
    Prostate 68:715-27. 2008
    ..Failure of cancer immunotherapy is essentially due to immunological tolerance to tumor-associated antigens (TAAs), as these antigens are also expressed in healthy tissues...
  41. pmc Role of the TMPRSS2-ERG gene fusion in prostate cancer
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 10:177-88. 2008
    ..Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer...
  42. ncbi request reprint Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arch Pathol Lab Med 130:989-96. 2006
    ..The metastasis-associated gene 1 (MTA1) is overexpressed in several human cancers. Recent reports suggest that MTA1 may play a role in cancer progression either through transcription repression and/or hormone receptor interactions...
  43. pmc Defining aggressive prostate cancer using a 12-gene model
    Tarek A Bismar
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Neoplasia 8:59-68. 2006
    ..0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process...
  44. ncbi request reprint How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden
    Ove Andrén
    Department of Urology, Orebro University Hospital, Orebro, Sweden
    J Urol 175:1337-40. 2006
    ..Therefore, identifying prognostic factors is increasingly important, notably among men diagnosed with localized prostate cancer, because many of them may not require aggressive treatment...
  45. ncbi request reprint Effect of finasteride on risk of prostate cancer: how little we really know
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Cell Biochem 91:478-82. 2004
    ..Confirmation of a spurious tumor grade "inflation" will make the conclusions of this study clearer and define the benefits of finasteride chemoprevention in a more favorable light...
  46. ncbi request reprint The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer
    Rainer Kuefer
    Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0944, USA
    Clin Cancer Res 9:6447-52. 2003
    ..The purpose of this study was to evaluate an 80 kDa proteolytic fragment of E-cadherin as a potential biomarker for prostate cancer progression and to identify putative proteases that are responsible for the cleavage of E-cadherin...
  47. ncbi request reprint Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations
    Lakshmi P Kunju
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Am J Clin Pathol 120:737-45. 2003
    ..Most HGPINs show diffuse moderate P504S staining. AAH may show focal P504S staining. We recommend using P504S along with morphologic examination and conventional basal cell markers...
  48. ncbi request reprint Prevention of prostate cancer with finasteride
    Mark A Rubin
    N Engl J Med 349:1569-72; author reply 1569-72. 2003
  49. ncbi request reprint Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis
    Zheng Fu
    Program in Immunology, School of Medicine, University of Michigan, Ann Arbor 48109 0940, USA
    J Natl Cancer Inst 95:878-89. 2003
    ..We examined whether RKIP functions as a suppressor of metastasis...
  50. ncbi request reprint Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions
    Caleb P Nelson
    Departments of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA
    Urol Oncol 21:213-8. 2003
    ..Tabulated 5-year PSA-free survival outcomes, stratified by these preoperative parameters, provide a basis for preoperative counseling of patients regarding postprostatectomy cancer control expectations...
  51. ncbi request reprint Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors
    Hassan Chaib
    Department of Urology, The University of Michigan, Ann Arbor 48109, USA
    Genes Chromosomes Cancer 37:306-13. 2003
    ....
  52. ncbi request reprint Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells
    Alexandre De La Taille
    Department of Urology, Assistance Publique des Hôpitaux de Paris CHU Mondor, 94000 Creteil, France
    Clin Cancer Res 9:1801-7. 2003
    ....
  53. ncbi request reprint Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer
    Daniel R Rhodes
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    J Natl Cancer Inst 95:661-8. 2003
    ....
  54. ncbi request reprint The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  55. ncbi request reprint High-density tissue microarray
    Woo Ho Kim
    Am J Surg Pathol 26:1236-8; discusson 1237-8. 2002
  56. ncbi request reprint Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer
    Rajal B Shah
    Deparment of Pathology and Urology, University of Michigan School of Medicine and Comprenhensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Am J Surg Pathol 26:1161-8. 2002
    ..p63 may be used as an alternative to 34betaE12 stain for difficult prostate lesions...
  57. pmc alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation
    Rainer Kuefer
    Department of Pathology, University of Michigan Medical School, Ann Arbor 48109 0602, USA
    Am J Pathol 161:841-8. 2002
    ..Taken together, these data suggest that AMACR expression is not hormone-dependent but may in fact be a marker of tumor differentiation...
  58. ncbi request reprint Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays
    Angelo M De Marzo
    Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231 1000, USA
    Hum Pathol 33:756-60. 2002
    ....
  59. pmc Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival
    Dinesh S Rao
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Clin Invest 110:351-60. 2002
    ..HIP1 represents a putative prognostic factor for prostate cancer and a potential therapy target in prostate as well as colon cancers...
  60. ncbi request reprint Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions
    Ming Zhou
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, USA
    Am J Surg Pathol 26:926-31. 2002
    ..In conclusion, our study suggests that AMACR is potentially an important tumor marker for several cancers and their precursor lesions, especially those linked to high-fat diets...
  61. ncbi request reprint Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate
    Sarajane Ross
    Department of Pathology, Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 62:2546-53. 2002
    ..Our results strongly suggest that maytansinoid-conjugated anti-PSCA monoclonal antibodies should be evaluated as a therapeutic modality for patients with advanced prostate cancer...
  62. ncbi request reprint The role of metastasis-associated protein 1 in prostate cancer progression
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 64:825-9. 2004
    ..In summary, this study identified an association of MTA1 expression and prostate cancer progression...
  63. pmc Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer
    Chandan Kumar-Sinha
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0602, USA
    Am J Pathol 164:787-93. 2004
    ..Taken together, our studies suggest that AMACR activity is increased in prostate cancer relative to benign epithelia and suggests that monitoring AMACR activity levels in prostate needle biopsies may have clinical applications...
  64. pmc Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, and the Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 164:831-40. 2004
    ..In the future, the AMACR AQUA Z-score may be useful in the automated screening and evaluation of prostate tissue biomarkers...
  65. pmc Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction
    Shao Yong Chen
    Cancer Biology Program, Hematology Oncology Division, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Mol Cell Biol 26:929-39. 2006
    ....
  66. ncbi request reprint Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer
    Phillip G Febbo
    Duke Institute for Genome Sciences and Policy, Division of Medical Oncology Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:152-8. 2006
    ....
  67. ncbi request reprint Autoantibody signatures in prostate cancer
    Xiaoju Wang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    N Engl J Med 353:1224-35. 2005
    ..New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer...
  68. ncbi request reprint Translational crossroads for biomarkers
    Robert C Bast
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:6103-8. 2005
    ....
  69. ncbi request reprint What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?
    Aurelien Descazeaud
    Department of Urology and Pathology, INSERMEMI03 3, Hopital Henri Mondor, Creteil, France
    Eur Urol 48:911-5. 2005
    ..This survey-based study examines what information urologists are extracting from prostate needle biopsy reports, and what they need for clinical management of prostate cancer (PC) patients...
  70. pmc Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells
    Charles J Dimitroff
    Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 65:5750-60. 2005
    ..These findings implicate a functional role of PSGL-1 in the bone tropism of prostate tumor cells and establish a new perspective into the molecular mechanism of human prostate tumor metastasis...
  71. ncbi request reprint Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death
    Mark A Rubin
    Department of Pathology Amory 3 195, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1424-32. 2005
    ..This is the first study to show that AMACR expression is significantly associated with prostate cancer progression and suggests that not all surrogate end points may be optimal to define biomarkers of aggressive prostate cancer...
  72. ncbi request reprint Reg IV: a promising marker of hormone refractory metastatic prostate cancer
    Zhennan Gu
    Department of Statistics, Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Cancer Res 11:2237-43. 2005
    ..In comparison, it is not expressed by any normal prostate specimens and only at low levels in approximately 40% of primary tumors. These data support Reg IV as a candidate marker for hormone refractory metastatic prostate cancer...
  73. ncbi request reprint Benign positive margins after radical prostatectomy means a poor prognosis--con
    Mark A Rubin
    Urology 65:221-3. 2005
  74. ncbi request reprint Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens
    Tara Jane Browne
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 35:1462-8. 2004
    ..However, a limitation of this approach is the loss of tissue in these small lesions, suggesting that combining AMACR and the BCC on a single slide would be superior to using either marker separately...
  75. ncbi request reprint Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
    Rajal B Shah
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Cancer Res 64:9209-16. 2004
    ..An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease...
  76. pmc Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neoplasia 6:503-12. 2004
    ..2-fold downregulation). Taken together, this study suggests that only a small subset of PCas may be amenable to tyrosine kinase inhibitors specific for PDGFR...
  77. ncbi request reprint Using molecular markers to predict outcome
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 172:S18-21; discussion S21-2. 2004
    ..Developing molecular tests to predict prostate cancer progression requires first defining meaningful clinical end points and defining strategies to take advantage of emerging technology...
  78. ncbi request reprint Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations
    Rajal B Shah
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor 48109, USA
    Am J Clin Pathol 122:517-23. 2004
    ..The cocktail provides a simple, cost-effective improvement in basal cell immunohistochemical analysis of difficult prostate lesions...
  79. ncbi request reprint JAGGED1 expression is associated with prostate cancer metastasis and recurrence
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 64:6854-7. 2004
    ....
  80. ncbi request reprint Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer
    Arun Sreekumar
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    J Natl Cancer Inst 96:834-43. 2004
    ..However, attempts to detect AMACR in circulation have not been successful. Hence, we determined whether an immune response to AMACR could be used as a serum biomarker for prostate cancer...
  81. ncbi request reprint Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors
    Pamela L Paris
    Comprehensive Cancer Center, University of California at San Francisco, 94115, USA
    Hum Mol Genet 13:1303-13. 2004
    ..Moreover, comparison with an independent set of metastases revealed approximately 40 candidate markers associated with metastatic potential. Copy number aberrations at these loci may define metastatic genotypes...
  82. ncbi request reprint alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    JAMA 287:1662-70. 2002
    ..Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens...

Research Grants13

  1. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2002
    ..abstract_text> ..
  2. "Molecular Signatures of Lethal and Indolent Prostate Cancer"
    Mark A Rubin; Fiscal Year: 2010
    ..At th conclusion of this proposal, we expect to have refined and fully validated molecular predictors of PCA deat as well as indolent PCA that is appropriate for further clinical development. ..
  3. Towards Understanding Prostate Cancer Heterogeneity
    Mark Rubin; Fiscal Year: 2009
    ..Finally, we will determine if FISH assays (or other in situ tests) can be employed as a prognostic biomarker. ..
  4. "Molecular Signatures of Lethal and Indolent Prostate Cancer"
    Mark Rubin; Fiscal Year: 2009
    ..At th conclusion of this proposal, we expect to have refined and fully validated molecular predictors of PCA deat as well as indolent PCA that is appropriate for further clinical development. ..
  5. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2006
    ..abstract_text> ..
  6. "Molecular Signatures of Lethal and Indolent Prostate Cancer"
    Mark Rubin; Fiscal Year: 2006
    ..At the conclusion of this proposal, we expect to have refined and fully validated molecular predictors of PCA death as well as indolent PCA that is appropriate for further clinical development. ..
  7. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2005
    ..abstract_text> ..
  8. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2004
    ..abstract_text> ..
  9. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2004
    ..abstract_text> ..
  10. Prostate Cancer Harbinger Genes
    Mark Rubin; Fiscal Year: 2003
    ..abstract_text> ..
  11. Towards Understanding Prostate Cancer Heterogeneity
    Mark A Rubin; Fiscal Year: 2010
    ..Finally, we will determine if FISH assays (or other in situ tests) can be employed as a prognostic biomarker. ..